Heidelberg Pharma AG (DE:HPHA)
XETRA:HPHA
HPHA Stock Chart & Stats
€2.40
€0.02(0.83%)
At close: 4:00 PM EST
€2.40
€0.02(0.83%)
Day’s Range― - ―
52-Week Range€2.33 - €5.36
Previous CloseN/A
Volume3.96K
Average Volume (3M)8.49K
Market Cap
€130.53M
Enterprise Value€116.72M
Total Cash (Recent Filing)€14.98M
Total Debt (Recent Filing)€1.16M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,784,317
10 Day Avg. Volume3,574
30 Day Avg. Volume8,494
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-12.31
Price to Sales (P/S)92.22
P/FCF Ratio-4.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€12.90M
Bulls Say, Bears Say
Bulls Say
Proprietary ATAC PlatformOwning a proprietary ATAC antibody‑drug conjugate platform provides a durable scientific moat: it enables multiple internal programs, creates potential for out‑licensing or partnerships, and concentrates R&D know‑how that can produce multiyear value beyond single trials.
Lower Reported Debt (2025)Reduced reported debt in 2025 lessens near‑term refinancing pressure and can extend strategic optionality. Lower leverage improves ability to pursue partnerships, negotiate non‑dilutive deals, or time equity raises, supporting operational continuity over several quarters.
Ability To Generate Gross ProfitHistorical periods of healthy gross profit indicate the core technology and program economics can deliver positive product‑level margins. If operating costs are controlled, this structural gross‑profit capability supports a credible path to sustainable margins as programs commercialize or scale.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow is a durable risk: it forces reliance on external financing or partner funding, increases dilution risk, and constrains the firm’s ability to fund clinical programs independently over the medium term without material capital raises.
Negative Shareholders' EquityStockholders’ equity turning negative is a structural red flag that reduces financial flexibility, can trigger covenant and counterparty concerns, and raises insolvency perception. It narrows strategic choices and elevates the cost and difficulty of obtaining non‑dilutive capital.
Ongoing Large Losses; Declining RevenueSustained operating and net losses combined with falling revenue undermine the path to profitability and heighten dependence on external funding. This structural earnings weakness erodes runway, complicates long‑term planning, and weakens bargaining power with partners and investors.
HPHA FAQ
What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest stock price was €2.33 and its highest was €5.36 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €130.53M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
Heidelberg Pharma AG’s upcoming earnings report date is Jul 15, 2026 which is in 97 days.
How were Heidelberg Pharma AG’s earnings last quarter?
Currently, no data Available
Is Heidelberg Pharma AG overvalued?
According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,784,317 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in DE:HPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heidelberg Pharma AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-391.55%
Trailing 12-Months
Asset Growth
-37.19%
Trailing 12-Months
Company Description
Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Technical Analysis
Biotest
―
B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Formycon AG
―